Information and advice on how to take care of yourself and your Parkinson’s during the COVID-19 outbreak
Precision medicine aims to define and treat Parkinson’s by tailoring the right therapy to each person, depending not only on their specific signs and symptoms, but also on the specific molecular signatures of their disease.
Analysis of the PPMI dataset has shown that compared to people with sporadic forms of Parkinson’s, newly diagnosed people carrying GBA mutations are less severely impaired, and those with LRRK2 mutations appear more mildly affected.
Skin cells have been used to characterize specific cellular problems in people with Parkinson’s, in a new approach that may help match them to particular drugs that may work best for them.
Parkinson’s affects women and men differently. This is reflected both in their different clinical features and progression, as well as in their experience of the condition.
Ambroxol was found to be safe and well tolerated in an open label trial in 18 people with Parkinson’s. It enters the brain and appears to increase levels of its chemical target GCase.